Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer

Last updated: October 4, 2021
Sponsor: Fujian Cancer Hospital
Overall Status: Active - Recruiting

Phase

3

Condition

Surgery

Stomach Cancer

Digestive System Neoplasms

Treatment

N/A

Clinical Study ID

NCT05035446
SILS+1-GC-001
  • Ages 18-75
  • All Genders

Study Summary

To evaluate the short-term outcomes of single-incision plus one-port laparoscopic surgery (SILS + 1) versus conventional laparoscopic surgery(CLS) for distal gastric cancer whose clinical stage was cT1-3N0-2M0

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • pathological diagnosis of gastric cancer
  • clinically diagnosed cT1b-3N0-2M0 lesions according to the 8th Edition of the AmericanJoint Committee on Cancer(AJCC) Cancer Staging Manual(measured using abdominal CT)
  • tumor size ≤ 5cm
  • planned to conduct subtotal gastrectomy

Exclusion

Exclusion Criteria:

  • preoperative radiotherapy and chemotherapy
  • tumor perforation
  • severe mental disease

Study Design

Total Participants: 120
Study Start date:
October 01, 2021
Estimated Completion Date:
August 31, 2022

Study Description

The gastric cancer patients with cT1-3N0-2M0 were randomized at a 1:1 ratio to the CLS group or the SILS+1group, then it will evaluate the short-term outcomes between two groups.

Connect with a study center

  • Fujian Cancer Hospital

    Fuzhou, Fujian 350014
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.